Clinical Trial Update: Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel plus prednisone with or without radiation for castration-resistant prostate cancer; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• Taxotere (docetaxel)

Snippet

Sponsor: Northwestern University | Conditions: PROSTATE CANCER | Phase 2 | Status: WITHDRAWN